Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;17(9):2108-2128.
doi: 10.1038/s41596-022-00709-3. Epub 2022 Jul 20.

The cell-line-derived subcutaneous tumor model in preclinical cancer research

Affiliations
Review

The cell-line-derived subcutaneous tumor model in preclinical cancer research

Stephen M Stribbling et al. Nat Protoc. 2022 Sep.

Abstract

Tumor-bearing experimental animals are essential for preclinical cancer drug development. A broad range of tumor models is available, with the simplest and most widely used involving a tumor of mouse or human origin growing beneath the skin of a mouse: the subcutaneous tumor model. Here, we outline the different types of in vivo tumor model, including some of their advantages and disadvantages and how they fit into the drug-development process. We then describe in more detail the subcutaneous tumor model and key steps needed to establish it in the laboratory, namely: choosing the mouse strain and tumor cells; cell culture, preparation and injection of tumor cells; determining tumor volume; mouse welfare; and an appropriate experimental end point. The protocol leads to subcutaneous tumor growth usually within 1-3 weeks of cell injection and is suitable for those with experience in tissue culture and mouse experimentation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ireson, C. R., Alavijeh, M. S., Palmer, A. M., Fowler, E. R. & Jones, H. J. The role of mouse tumour models in the discovery and development of anticancer drugs. Br. J. Cancer 121, 101–108 (2019). - PubMed - PMC - DOI
    1. Herter-Sprie, G. S., Kung, A. L. & Wang, K.-K. New cast for a new era: preclinical cancer drug development revisited. J. Clin. Invest. 123, 3639–3645 (2013). - PubMed - PMC - DOI
    1. Damia, G. & D´Incalci, M. Contemporary pre-clinical development of anticancer agents—what are the optimal preclinical models? Eur. J. Cancer 45, 2768–2781 (2009). - PubMed - DOI
    1. Ahmad, A. S., Ormiston-Smith, N. & Sasieni, P. D. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br. J. Cancer 112, 943–947 (2015). - PubMed - PMC - DOI
    1. Morton, C. L. & Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc. 2, 247–250 (2007). - PubMed - DOI

LinkOut - more resources